319 related articles for article (PubMed ID: 27805254)
1. Effect of a novel oral chemotherapeutic agent containing a combination of trifluridine, tipiracil and the novel triple angiokinase inhibitor nintedanib, on human colorectal cancer xenografts.
Suzuki N; Nakagawa F; Matsuoka K; Takechi T
Oncol Rep; 2016 Dec; 36(6):3123-3130. PubMed ID: 27805254
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
Nukatsuka M; Nakagawa F; Takechi T
Anticancer Res; 2015 Sep; 35(9):4605-15. PubMed ID: 26254349
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts.
Tsukihara H; Nakagawa F; Sakamoto K; Ishida K; Tanaka N; Okabe H; Uchida J; Matsuo K; Takechi T
Oncol Rep; 2015 May; 33(5):2135-42. PubMed ID: 25812794
[TBL] [Abstract][Full Text] [Related]
4. [
Kim SY; Jung JH; Lee HJ; Soh H; Lee SJ; Oh SJ; Chae SY; Lee JH; Lee SJ; Hong YS; Kim TW; Moon DH
Cancer Res; 2017 Dec; 77(24):7120-7130. PubMed ID: 29055019
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and Safety of Regorafenib vs. Trifluridine/Tipiracil in Unresectable Colorectal Cancer: A Retrospective Cohort Study.
Nakashima M; Takeuchi M; Kawakami K
Clin Colorectal Cancer; 2020 Dec; 19(4):e208-e225. PubMed ID: 32912821
[TBL] [Abstract][Full Text] [Related]
6. Monitoring trifluridine incorporation in the peripheral blood mononuclear cells of colorectal cancer patients under trifluridine/tipiracil medication.
Nakanishi R; Kitao H; Kiniwa M; Morodomi Y; Iimori M; Kurashige J; Sugiyama M; Nakashima Y; Saeki H; Oki E; Maehara Y
Sci Rep; 2017 Dec; 7(1):16969. PubMed ID: 29208954
[TBL] [Abstract][Full Text] [Related]
7. Effective Sequential Combined Chemotherapy with Trifluridine/Tipiracil and Regorafenib in Human Colorectal Cancer Cells.
Matsuoka K; Nakagawa F; Tanaka N; Okabe H; Matsuo K; Takechi T
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257515
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with irinotecan hydrochloride on human colorectal and gastric cancer xenografts.
Nukatsuka M; Nakagawa F; Saito H; Sakata M; Uchida J; Takechi T
Anticancer Res; 2015 Mar; 35(3):1437-45. PubMed ID: 25750295
[TBL] [Abstract][Full Text] [Related]
9. Self-Reported Adherence to Trifluridine and Tipiracil Hydrochloride for Metastatic Colorectal Cancer: A Retrospective Cohort Study.
Sugita K; Kawakami K; Yokokawa T; Sugisaki T; Takiguchi T; Aoyama T; Suzuki K; Suenaga M; Yamaguchi K; Inoue A; Machida Y; Yamaguchi T; Hama T
Oncology; 2016; 91(4):224-230. PubMed ID: 27513940
[TBL] [Abstract][Full Text] [Related]
10. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama C; Denda T; Satake H; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Sugiyama M; Komatsu Y; Okuyama H; Baba E; Sakai D; Watanabe T; Tamura T; Yamashita K; Gosho M; Shimada Y
Oncologist; 2018 Jan; 23(1):7-15. PubMed ID: 28894015
[TBL] [Abstract][Full Text] [Related]
11. Trifluridine/Tipiracil: A Review in Metastatic Colorectal Cancer.
Burness CB; Duggan ST
Drugs; 2016 Sep; 76(14):1393-402. PubMed ID: 27568360
[TBL] [Abstract][Full Text] [Related]
12. Salvage Therapy After Regorafenib or Trifluridine/Tipiracil Treatment of Metastatic Colorectal Cancer: A Conditional Landmark Analysis.
Nakashima M; Takeuchi M; Tanaka S; Kawakami K
Anticancer Res; 2021 Feb; 41(2):1055-1062. PubMed ID: 33517315
[TBL] [Abstract][Full Text] [Related]
13. Trifluridine/tipiracil increases survival rates in peritoneal dissemination mouse models of human colorectal and gastric cancer.
Suzuki N; Nakagawa F; Takechi T
Oncol Lett; 2017 Jul; 14(1):639-646. PubMed ID: 28693216
[TBL] [Abstract][Full Text] [Related]
14. The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective.
Chan BM; Hochster HS; Lenz HJ
Am J Health Syst Pharm; 2019 Feb; 76(6):339-348. PubMed ID: 31361848
[TBL] [Abstract][Full Text] [Related]
15. A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone.
Cleary JM; Rosen LS; Yoshida K; Rasco D; Shapiro GI; Sun W
Invest New Drugs; 2017 Apr; 35(2):189-197. PubMed ID: 28111727
[TBL] [Abstract][Full Text] [Related]
16. A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancer.
Moehler M; Michel M; Stein A; Trojan J; Marquardt J; Tintelnot J; Waidmann O; Weinmann A; Woerns MA; Schroeder H; Maenz M; Foerster F
Future Oncol; 2021 Sep; 17(25):3309-3319. PubMed ID: 33993741
[TBL] [Abstract][Full Text] [Related]
17. Adherence, Dosing, and Managing Toxicities With Trifluridine/Tipiracil (TAS-102).
Lee JJ; Chu E
Clin Colorectal Cancer; 2017 Jun; 16(2):85-92. PubMed ID: 28242161
[TBL] [Abstract][Full Text] [Related]
18. Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer.
Argilés G; André T; Hollebecque A; Calvo A; Dahan L; Cervantes A; Leger C; Amellal N; Fougeray R; Tabernero J
Eur J Cancer; 2019 May; 112():12-19. PubMed ID: 30889492
[TBL] [Abstract][Full Text] [Related]
19. Radiosensitisation and enhanced tumour growth delay of colorectal cancer cells by sustained treatment with trifluridine/tipiracil and X-rays.
Rothkamm K; Christiansen S; Rieckmann T; Horn M; Frenzel T; Brinker A; Schumacher U; Stein A; Petersen C; Burdak-Rothkamm S
Cancer Lett; 2020 Nov; 493():179-188. PubMed ID: 32891715
[TBL] [Abstract][Full Text] [Related]
20. Influence of precedent drug on the subsequent therapy in the sequence of trifluridine/tipiracil with/out bevacizumab and regorafenib for unresectable or recurrent colorectal cancer.
Oshima K; Hirano H; Shoji H; Iwasa S; Okita N; Takashima A; Boku N
PLoS One; 2022; 17(6):e0269115. PubMed ID: 35653412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
